Tigecycline combined with cefoperazone-sulbactam in treatment of hospital-acquired pneumonia caused by extensively drug resistant Acinetobacter baumannii
- VernacularTitle:替加环素联合头孢哌酮-舒巴坦治疗广泛耐药鲍曼不动杆菌医院获得性肺炎临床疗效观察
- Author:
Youfa QIN
;
Lei WU
;
Yongkun ZHU
;
Yang ZHANG
- Publication Type:Journal Article
- Keywords:
cefoperazone-sulbactam;
tigecycline;
Acinetobacter baumannii;
extensively drug resistant
- From:
Chinese Journal of Infection and Chemotherapy
2015;(5):430-433
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy of tigecycline in combination with cefoperazone‐sulbactam for treatment of hospital‐acquired pneumonia caused by extensively drug resistant Acinetobacter baumannii .Methods A total of 53 patients with hospital‐acquired pneumonia caused by extensively drug resistant A .baumannii were randomized to receive tigecycline plus cefoperazone‐sulbactam ,or tigecycline alone as control .The duration of treatment was 14 days for both groups .Results The combination therapy group was superior to control group in terms of overall efficacy rate(70 .4% vs 38 .5% ,P=0 .020) .The bacterial clearance rate (55 .6% vs 38 .5% ,P>0 .05)and incidence of adverse reactions (14 .3% vs 15 .4% ,P>0 .05)did not show significant difference between the two treatment groups .Conclusions High dose cefoperazone‐sulbactam can improve the antimicrobial activity of tigecycline in the treatment of hospital‐acquired pneumonia caused by extensively drug resistant A . baumannii ,which may be a new therapy strategy for such infections .
